Abstract
The objective of this study was to assess the prevalence and pattern of neuropsychological impairment in cohorts of human immunodeficiency virus (HIV)-infected individuals across pre- and post-HAART (highly active antiretroviral therapy) eras. Two cohorts of HIV-infected individuals attending tertiary referral hospital outpatient clinics were studied. The cohorts represented two eras of antiretroviral medication: monotherapy (n = 51) and HAART (n = 90). Each was compared in nine neuropsychological domains in regard to the prevalence as well as pattern of neuropsychological impairment. Because the authors intended to characterize the prevalence and pattern of neuropsychological deficits in nondemented advanced HIV-infected individuals, patients with a current diagnosis of acquired immunodeficiency syndrome (AIDS) dementia complex were not included. The prevalence of impairment was not significantly different across pre-HAART and HAART eras using a standard criterion to define impairment: −2 SD in two neuropsychological measures (41.1%/38.8%). Prevalence of deficits was not significantly reduced in patients with undetectable plasma viral load. The pattern of neuropsychological impairment was different across pre-HAART and HAART eras, with an improvement in attention, verbal fluency, visuoconstruction deficits, but a deterioration in learning efficiency and complex attention. This change remained even in patients with an undetectable plasma viral load, although the severity was partially diminished. Neuropsychological deficits remain common in the HAART era, essentially uninfluenced by HAART. The finding that some neuropsychological functions are improving while other are deteriorating indicates that these deficits do not reflect “burnt out” damage but rather that there is an active intracerebral process occurring, the nature of which is still to be determined.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antinori A, Giancola ML, et al (2003). Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 16: 1867–1876.
Brew BJ (2001). AIDS dementia complex in HIV neurology. Oxford: Oxford University Press, pp. 53–90.
Brew BJ (2004). Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 18: S75-S78.
Brew BJ, Brown SJ, et al (1998). Safety and efficacy of Abacavir (ABC, 1952) in AIDS dementia complex (Study CNAB 3001). In: 12th World AIDS Conference, Geneva, 28 June–3 July.
Brew BJ, Pemberton L, et al (1997). Levels of human Immunodeficiency virus type 1RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 175: 963–966.
Butters N, Grant I, et al (1990). Assessment of AIDS-related cognitive changes: recommendations of the NIMH workgroup on neuropsychological assessment approaches. J Clin Exp Neuropsychol 12: 963–978.
Crowe S, Benedict T, et al (1999). Cognitive determinants of performance on the Digit Symbol-coding test, the Symbol Search Test of the WAIS-III, and the Symbol Digit Modalities Test: an analysis in a healthy sample. Aust Psychol 34: 204–210.
Cunningham P, Smith D, et al (2000). Evidence for independent development of reverse transcriptase inhibitor resistance patterns in the cerebrospinal fluid. AIDS 14: 1949–1954.
Cysique L, Maruff P, et al (in press). Antiretroviral therapy in HIV-infection: are neurologically active drugs important? Arch Neurol
Dore GJ, Correll PK, et al (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13: 1249–1253.
Dore GJ, McDonald A, et al (2003). Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17: 1539–1545.
Dunbar N, Perdices M, et al (1992). Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS. AIDS 6: 691–700.
Ellis RJ, Hsia K, et al (1997). Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neuro cognitively impaired individuals with Acquired Immuno Deficiency Syndrome. Ann Neurol 42(5): 679–688.
Ferrando S, Van Gorp W, et al (1998). Highly active antiretroviral treatment in HIV infection: benefits for neuropsychological function. AIDS 12: F65-F70.
Goodkin K, Wilkie FL, et al (2001). Aging and neuro-AIDS conditions and the changing spectrum of HIV-1 associated morbidity and mortality. J Clin Epidemiol 54: S35-S43.
Grunseit AC, Perdices M, et al (1994). Neuropsychological function in asymptomatic HIV-1 infection: methodological issues. J Clin Exp Neuropsychol 16: 898–910.
Heaton R, Grant I, et al (1995). The HNRC 500Neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc 1: 231–251.
Hirschel B, Opravil M (1999). The year in review: antiretroviral treatment. AIDS 13: S177-S187.
Howell DC (2002) Statistical methods for psychology, 5th ed. Duxbury: Thomson Learning.
Lezak MD (1995) Neuropsychological assessment, 4th ed. New York: Oxford University Press.
Lovibond SH, Lovibond PF (1995) Manual for the Depression Anxiety Stress Scales (2nd. Ed.). Sydney: Psychology Foundation.
McArthur JC, Hoover DR, et al (1993). Dementia in AIDS patients: incidence and risk factors. Neurology 43: 2245–2252.
McArthur JC, McClernon DR, et al (2002). Viral load markers and neurological status: a report from the North-East Dementia Cohort. J NeuroVirol 8(Suppl 1): Abstract 19.
McArthur JC, McDermott MP, et al (In press). Attenuated CNS infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol
Mc Donald A (2002). HIV/AIDS, viral hepatitis and sexually transmissible infections. In: Australia Annual Surveillance Report 2002. National Centre in HIV Epidemiology and Clinical Research University of New South Wales Sydney.
Moore RD, Chaisson RE (1999). Natural History of HIV infection in the era of combination antiretroviral therapy. AIDS 13: 1993–1942.
Neuenburg JK, Brodt HR, et al (2002). HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31: 171–177.
Perneger TV (1998). What’s wrong with Bonferroni adjustments. BMJ 316: 1236–1238.
Radloff LS (1977). The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Measure 1: 385–401.
Sacktor N, McDermott M, et al (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol 8: 136–142.
Sacktor N, Tarwater PM, et al (2001). CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 57: 542–544.
Sacktor NC, Bacellar H, et al (1996). Psychomotor slowing in HIV infection: a predictor of dementia, AIDS and death. J NeuroVirol 2: 404–410.
Sacktor NC, Lyles RH, et al (1999). Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Neurology 52: 1640–1647.
Smith A. (1982) Symbol Digit Modalities Test manual. Los Angeles: Western Psychological Services.
Spielberger CD, Gorsuch RL, Lushene RE (1970). Manual for the State-Trail Anxiety Inventory. Palo Alto: Consulting Clinical Psychologists Press.
Suarez S, Baril L, et al (2001). Outcome of patients with HIV-1 related cognitive impairment on highly active antiretroviral therapy. AIDS 15: 192–200.
Tozzi V, Balestra P, et al (1999). Positive and sustained effects of highly active antiretroviral therapy on HIV-1 associated neurocognitive impairment. AIDS 13: 1889–1897.
Tozzi V, Balestra P, et al (2001). Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 28: 19–27.
Venturi G, Catucci M, et al (2000). Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 181: 740–745.
Zakzanis KK (2001). Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect sizes analyses for neuropsychological researchers. Arch Clin Neuropsychol 16: 653–667.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was supported by the University of New South Wales Doctoral Scholarship and the NIH grant NS43103.
Rights and permissions
About this article
Cite this article
Cysique, L.A., Maruff, P. & Brew, B.J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: A combined study of two cohorts. Journal of NeuroVirology 10, 350–357 (2004). https://doi.org/10.1080/13550280490521078
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280490521078